Diligence memo · auto-generated · as of July 2, 2026
Pathos AI, Inc.
Pathos AI, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Pathos AI, Inc. operates in Biotechnology, based in CHICAGO.
Sub-sector tags: ai/ml.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pathos AI, Inc. has raised $365M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $283M on 2025-04-17.
Most recent recorded round closed around 2025-04-17.
Valuation (modeled)modeled
Provath models Pathos AI, Inc. at approximately $2.4B (range $1.3B–$3.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.70× the median modeled value of Series D+ Biotechnology companies in 2025–2027 (33 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 14 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 4.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 99% of Biotechnology peers (4293 compared).
Modeled value ranks above 95% of those peers.
Closest niche peers: Kriya Therapeutics, Inc., Sensei Biotherapeutics, Inc., Odyssey Therapeutics, Inc., Rhodenergy An Environmental Co Corp, Tectonic Therapeutic, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.